Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

Novel Management of Immune Thrombocytopenia in Gaucher Disease Patients

Hanna Rosenbaum, MD

Blood (2014) 124 (21): 5006.

https://doi.org/10.1182/blood.V124.21.5006.5006

Published: 2014

Journal Articles

Azacitidine and Lenalidomide Combination In Higher-Risk Myelodysplastic Syndromes-Preliminary Results Of The Vilen-01 Protocol

Moshe Mittelman, MD, Kalman Filanovsky, MD, Hanna Rosenbaum, MD, Pia Raanani, MD, Andrei Braester, MD, Neta Goldschmidt, MD, Ilana Hellman, PhD, Ilya Kirgner, MD, Chava Perri, Howard S Oster, MD, PhD

Blood (2013) 122 (21): 1576.

https://doi.org/10.1182/blood.V122.21.1576.1576

Published: 2013

Journal Articles

Eliglustat, an Investigational Oral Therapy for Gaucher Disease Type 1: Phase 2 Results After 4 Years of Treatment

M. Judith Peterschmitt, MD, Elena Lukina, PhD, MD, Nora Watman, MD, Marta Dragosky, M.D., Gregory M Pastores, Elsa Avila Arreguin, M.D., Hanna Rosenbaum, MD, Ari Zimran, MD, Elena Sysoeva, Rasha Aguzzi, Leorah H Ross, Ana Cristina Puga, M.D.

Blood (2012) 120 (21): 1038.

https://doi.org/10.1182/blood.V120.21.1038.1038

Published: 2012

Journal Articles

Increased Incidence of Autoimmune and Lymphoproliferative Disorders in Gaucher Patients Accompanied with Significantly Impaired Dendritic Cell Function,

Hanna Rosenbaum, MD, Noam Bettman, MSc., Tamar Katz, Ph.D, Irit Avivi, MD

Blood (2011) 118 (21): 3211.

https://doi.org/10.1182/blood.V118.21.3211.3211

Published: 2011

Journal Articles

Improvements in Skeletal Manifestations in Gaucher Disease Type 1 Patients After 3 Years of Treatment with Oral Eliglustat During a Phase 2 Trial,

M. Judith Peterschmitt, MD, Ravi S Kamath, MD, Elena Lukina, PhD, MD, Nora Watman, MD, Marta Dragosky, M.D., Marcelo Iastrebner, M.D., Gregory M Pastores, Elsa Avila Arreguin, M.D., Mici Phillips, M.D., Hanna Rosenbaum, MD, Elena Sysoeva, Rasha Aguzzi, Leorah H Ross, Ana Cristina Puga, M.D., Daniel I Rosenthal, M.D.

Blood (2011) 118 (21): 3216.

https://doi.org/10.1182/blood.V118.21.3216.3216

Published: 2011

Journal Articles

Eliglustat, An Investigational Oral Therapy for Gaucher Disease Type 1: Phase 2 Results After 3 Years

M. Judith Peterschmitt, MD, Elena Lukina, PhD, MD, Nora Watman, MD, Marta Dragosky, M.D., Marcelo Iastrebner, M.D., Gregory Pastores, M.D., Elsa Avila Arreguin, M.D., Mici Phillips, M.D., Hanna Rosenbaum, MD, Elena Sysoeva, Rasha Aguzzi, Leorah H Ross, Ana Cristina Puga, M.D.

Blood (2011) 118 (21): 1104.

https://doi.org/10.1182/blood.V118.21.1104.1104

Published: 2011

Journal Articles

Contribution of Decreased Migration of Monocytes to Impaired Inflammation in Gaucher Disease

Tamar Katz, Ph.D, Noam Bettman, MSc., Hanna Rosenbaum, MD, Irit Avivi, MD

Blood (2011) 118 (21): 2162.

https://doi.org/10.1182/blood.V118.21.2162.2162

Published: 2011

Journal Articles

Gaucher Disease and Multiple Myeloma: A Diagnostic and Treatment Challenge

Hanna Rosenbaum, MD, Irit Avivi, MD, Eliezer A. Rachmilewitz, Paulina Petchenko, MD

Blood (2011) 118 (21): 2166.

https://doi.org/10.1182/blood.V118.21.2166.2166

Published: 2011

Journal Articles

For Standard and High-Risk Patients with Hodgkin Lymphoma Six Cycles of Tailored BEACOPP, Based On Interim Scintigraphy, Are Effective and Female Fertility Is Preserved.

Eldad Dann, MD, Rachel Bar-Shalom, MD, Ada Tamir, PhD, Menachem Ben-Shachar, MD, Irit Avivi, MD, Tsila Zuckerman, MD, Nuhad Haddad, MD, Hanna Rosenbaum, MD, Riva Fineman, MD, Odelia Goor, MD, Diana Libster, MD, Zeev Blumenfeld, MD, Jacob M. Rowe, MD, Ron Epelbaum, MD

Blood (2009) 114 (22): 1552.

https://doi.org/10.1182/blood.V114.22.1552.1552

Published: 2009

Journal Articles

Genz-112638 for Gaucher Disease Type 1: Phase 2 Clinical Trial Results After 18 Months of Treatment.

Judith Peterschmitt, MD, Elena Lukina, PhD, MD, Nora Patricia Watman, MD, Elsa Avila Arreguin, MD, Maryam Banikazemi, MD, Gregory Pastores, MD, Marcelo Iastrebner, MD, Marta Dragosky, MD, Hanna Rosenbaum, MD, Mici Phillips, MD, Mathilde Kaper, Tejdip Singh, MD, Ana Cristina Puga, MD, PhD

Blood (2009) 114 (22): 1349.

https://doi.org/10.1182/blood.V114.22.1349.1349

Published: 2009

Journal Articles

Immune Thrombocytopenia in Type I Gaucher Disease.

Hanna Rosenbaum, MD, Tina Napso, MS.c, Lilach Bonstein, Ph.D

Blood (2007) 110 (11): 3200.

https://doi.org/10.1182/blood.V110.11.3200.3200

Published: 2007

Journal Articles

Type I Gaucher Disease and Parkinsonism: Prevalence of Parkinson Disease among Ashkenazi Family Members Who Are Carriers of Gaucher Disease.

Hanna Rosenbaum, MD, Judith Aharon-Peretz, MD, Ruth Gershoni-Baruch, MD, Jacob M. Rowe4, MD

Blood (2005) 106 (11): 3871.

https://doi.org/10.1182/blood.V106.11.3871.3871

Published: 2005

NARROW

Novel Management of Immune Thrombocytopenia in Gaucher Disease Patients

Azacitidine and Lenalidomide Combination In Higher-Risk Myelodysplastic Syndromes-Preliminary Results Of The Vilen-01 Protocol

Eliglustat, an Investigational Oral Therapy for Gaucher Disease Type 1: Phase 2 Results After 4 Years of Treatment

Increased Incidence of Autoimmune and Lymphoproliferative Disorders in Gaucher Patients Accompanied with Significantly Impaired Dendritic Cell Function,

Improvements in Skeletal Manifestations in Gaucher Disease Type 1 Patients After 3 Years of Treatment with Oral Eliglustat During a Phase 2 Trial,

Eliglustat, An Investigational Oral Therapy for Gaucher Disease Type 1: Phase 2 Results After 3 Years

Contribution of Decreased Migration of Monocytes to Impaired Inflammation in Gaucher Disease

Gaucher Disease and Multiple Myeloma: A Diagnostic and Treatment Challenge

For Standard and High-Risk Patients with Hodgkin Lymphoma Six Cycles of Tailored BEACOPP, Based On Interim Scintigraphy, Are Effective and Female Fertility Is Preserved.

Genz-112638 for Gaucher Disease Type 1: Phase 2 Clinical Trial Results After 18 Months of Treatment.

Immune Thrombocytopenia in Type I Gaucher Disease.

Type I Gaucher Disease and Parkinsonism: Prevalence of Parkinson Disease among Ashkenazi Family Members Who Are Carriers of Gaucher Disease.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only